Please assess the completion status of the following clinical trial:

Trial Title: Daily vs. Non-Daily SBRT for NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age (no upper age limit).~* A diagnosis of non-small cell lung cancer, T1-2 N0 M0 either with histologic confirmation or with documented interval growth of the index lesion on two interval computed tomography (CT) chest scans and an SUVmax of the lesion ≥ 3.0 on a pretreatment PET scan.~* Patient must be deemed medically inoperable or refuse surgery.~* Radiographic evaluation of the mediastinum and distant sites with a CT scan of the chest and PET scan.~* For T2b N0 patients, radiographic evaluation of the brain with magnetic resonance imaging (MRI) of the brain unless the patient has contraindications to an MRI scan (in which case a CT scan of the head is necessary).~* For central T1 N0 and all T2 N0 patients, pathologic sampling (either via endobronchial ultrasound-guided biopsy \[EBUS\] or mediastinoscopy) of mediastinal lymph nodes is required.~* ECOG Performance Status 0-2.~* For women of childbearing potential, negative pregnancy test within 2 weeks prior to SBRT treatment.~* Patients must be deemed able to comply with the treatment plan and follow-up schedule.~* Patients must provide specific informed consent prior to study entry.~* Women of childbearing potential and male participants who are sexually active must use adequate contraception during treatment and for 6 weeks following treatment.~Exclusion Criteria:~* Prior history of radiation therapy to the thorax that would likely increase the risk of serious complications from the radiotherapy delivered on this protocol.~* Prior history of lung cancer.~* Currently taking disease-modifying rheumatoid drugs (DMRDs).~* Severe, active co-morbidity, defined as follows:~* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.~* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Note, however, that coagulation parameters are not required for entry into this protocol.~* Prior organ transplant.~* Systemic lupus.~* Psoriatic arthritis.~* Known to be HIV positive. HIV-positive patients are known to have worse clinical outcomes, especially for local, regional, and distant cancer control. This poorer prognosis is thought to be secondary to a compromised immune system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Consecutive Daily Treatment (Type: OTHER): Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
- Non-Consecutive Daily Treatment (Type: OTHER): Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues